• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results

    5/8/25 4:01:00 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care
    Get the next $CODX alert in real time by email

    SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025.

    First Quarter 2025 Financial Results:

     ●Revenue of $0.1 million, which declined from $0.5 million during the Q1 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the first quarter 2025
       
     ●Operating expenses of $8.6 million decreased by 18.2% from the prior year first quarter
       
     ●Operating loss of $8.6 million compared to operating loss of $10.3 million in Q1 2024
       
     ●Net loss of $7.5 million, compared to net loss of $9.3 million in Q1 2024, representing a loss of $0.24 per fully diluted share, compared to a loss of $0.31 per fully diluted share in Q1 2024
       
     ●Adjusted EBITDA loss of $7.4 million
       
     ●Cash, cash equivalents, and marketable securities of $21.5 million as of March 31, 2025
       

    First Quarter Business Highlights:

     ●Remain on track for initiation of clinical evaluations for 4 tests in product pipeline and completion of manufacturing facility in India by year-end 2025
       
     ●Hosted a symposium to honor International HPV Awareness Day 2025 in India, in collaboration with CoSara, as the Company prepares for pre-clinical and pre-analytical studies for its HPV test to be utilized on the Co-Dx™ PCR Pro™ instrument*
       
     ●Hosted a booth at BioUtah's Life Sciences Day on the Hill at the Utah State Capitol Rotunda, which showcased Co-Dx's upcoming at-home and point-of-care Co-Dx PCR platform*
       

    "During the quarter, Co-Diagnostics continued to make significant progress in the development of our test pipeline," said Dwight Egan, Co-Diagnostics' Chief Executive Officer. "Our priority remains bringing the Co-Dx PCR platform to market, as we advance towards clinical evaluations and regulatory submissions for the 4 main tests in our pipeline. We believe our tuberculosis, respiratory multiplex, HPV multiplex, and COVID-19 tests, to be utilized on the Co-Dx PCR Pro, will play a key role in transforming the global accessibility of diagnostic testing solutions. I am proud of the progress our team has made and look forward to building upon our momentum throughout the rest of the year."

    "Our team made strong progress on our development pipeline during the quarter. Co-Diagnostics remains focused on maintaining operational efficiency as we advance towards several development milestones, including the commencement of clinical evaluations. We look forward to providing you with updates as they come," said Brian Brown, Co-Diagnostics' Chief Financial Officer.

    Conference Call and Webcast

    Co-Diagnostics will host a conference call and webcast at 4:30 p.m. EDT today to discuss its financial results with analysts and institutional investors. The conference call and webcast will be available via:

    Webcast: ir.codiagnostics.com on the Events & Webcasts page, or accessible directly here

    Conference Call: 800-715-9871 (Toll Free) or (646) 307-1963 (Toll) with participant passcode 1977478

    The call will be recorded and later made available on the Company's website: https://codiagnostics.com.

    *The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

    About Co-Diagnostics, Inc.

    Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.

    Non-GAAP Financial Measures:

    This press release contains adjusted EBITDA, which is a non-GAAP measure defined as net income excluding depreciation, amortization, income tax (benefit) expense, net interest (income) expense, stock-based compensation, change in fair value of contingent consideration, and realized gain (loss) on investments. The Company believes that adjusted EBITDA provides useful information to management and investors relating to its results of operations. The Company's management uses this non-GAAP measure to compare the Company's performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The Company believes that the use of adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company's financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

    Management does not consider the non-GAAP measure in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of the non-GAAP financial measure is that it excludes significant expenses that are required by GAAP to be recorded in the Company's financial statements. In order to compensate for these limitations, management presents the non-GAAP financial measure together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of the net income, the most comparable GAAP financial measure to adjusted EBITDA, is included at the end of this release. The Company urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company's business.

    Forward-Looking Statements:

    This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding (i) advancement into clinical evaluations and continued development and regulatory submissions for the Co-Dx PCR platform and (ii) our belief that the platform will play a key role in transforming the global accessibility of diagnostic testing solutions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 27, 2025, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

    Investor Relations Contact:

    Andrew Benson

    Head of Investor Relations

    +1 801-438-1036

    [email protected]

    CO-DIAGNOSTICS, INC. AND SUBSIDIARIES
    CONSOLIDATED BALANCE SHEETS
    (Unaudited)
           
      March 31, 2025  December 31, 2024 
    Assets        
    Current assets        
    Cash and cash equivalents $1,903,034  $2,936,544 
    Marketable investment securities  19,575,902   26,811,098 
    Accounts receivable, net  136,391   132,570 
    Inventory, net  1,083,309   1,072,724 
    Income taxes receivable  574   - 
    Prepaid expenses and other current assets  1,132,281   1,338,762 
    Total current assets  23,831,491   32,291,698 
    Property and equipment, net  2,593,808   2,761,280 
    Operating lease right-of-use asset  1,893,422   2,114,876 
    Intangible assets, net  26,101,000   26,101,000 
    Investment in joint venture  729,621   731,065 
    Total assets $55,149,342  $63,999,919 
    Liabilities and stockholders' equity        
    Current liabilities        
    Accounts payable $2,712,642  $3,294,254 
    Accrued expenses  1,610,890   2,562,169 
    Operating lease liability, current  902,881   915,619 
    Contingent consideration liabilities, current  109,275   502,819 
    Deferred revenue  40,857   40,857 
    Total current liabilities  5,376,545   7,315,718 
    Long-term liabilities        
    Income taxes payable  725,127   713,643 
    Operating lease liability  1,028,282   1,236,560 
    Contingent consideration liabilities  98,557   422,080 
    Total long-term liabilities  1,851,966   2,372,283 
    Total liabilities  7,228,511   9,688,001 
    Commitments and contingencies (Note 10)        
    Stockholders' equity        
    Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively  -   - 
    Common stock, $0.001 par value; 100,000,000 shares authorized; 38,421,321 shares issued and 33,572,643 shares outstanding as of March 31, 2025 and 37,902,222 shares issued and 33,053,544 shares outstanding as of December 31, 2024  38,421   37,902 
    Treasury stock, at cost; 4,848,678 shares held as of March 31, 2025 and December 31, 2024, respectively  (15,575,795)  (15,575,795)
    Additional paid-in capital  103,701,665   102,472,210 
    Accumulated other comprehensive income  330,653   418,443 
    Accumulated earnings (deficit)  (40,574,113)  (33,040,842)
    Total stockholders' equity  47,920,831   54,311,918 
    Total liabilities and stockholders' equity $55,149,342  $63,999,919 



    CO-DIAGNOSTICS, INC. AND SUBSIDIARIES
    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
    (Unaudited)
        
      Three Months Ended March 31, 
      2025  2024 
    Product revenue $50,277  $252,745 
    Grant revenue  -   215,109 
    Total revenue  50,277   467,854 
    Cost of revenue  21,590   234,505 
    Gross profit  28,687   233,349 
    Operating expenses        
    Sales and marketing  657,030   1,563,682 
    General and administrative  2,773,149   2,918,803 
    Research and development  4,870,019   5,679,678 
    Depreciation and amortization  280,445   330,573 
    Total operating expenses  8,580,643   10,492,736 
    Loss from operations  (8,551,956)  (10,259,387)
    Other income, net        
    Interest income, net  13,601   362,733 
    Realized gain on investments  301,465   228,070 
    Gain on remeasurement of acquisition contingencies  717,067   450,260 
    Loss on equity method investment in joint venture  (1,444)  (70,955)
    Total other income, net  1,030,689   970,108 
    Loss before income taxes  (7,521,267)  (9,289,279)
    Income tax provision  12,004   22,764 
    Net loss $(7,533,271) $(9,312,043)
    Other comprehensive income (loss)        
    Change in net unrealized gains on marketable securities, net of tax  (87,790)  79,855 
    Total other comprehensive income (loss) $(87,790) $79,855 
    Comprehensive loss $(7,621,061) $(9,232,188)
             
    Loss per common share:        
    Basic and Diluted $(0.24) $(0.31)
    Weighted average shares outstanding:        
    Basic and Diluted  32,048,953   29,842,874 



    CO-DIAGNOSTICS, INC. AND SUBSIDIARIES
    GAAP AND NON-GAAP MEASURES
    (Unaudited)
           
    Reconciliation of net loss to adjusted EBITDA:      
      Three Months Ended March 31, 
      2025  2024 
    Net loss $(7,533,271) $(9,312,043)
    Interest income, net  (13,601)  (362,733)
    Realized gain on investments  (301,465)  (228,070)
    Depreciation and amortization  280,445   330,573 
    Change in fair value of contingent consideration  (717,067)  (450,260)
    Stock-based compensation expense  875,228   1,571,234 
    Income tax provision  12,004   22,764 
    Adjusted EBITDA $(7,397,727) $(8,428,535)


    Primary Logo

    Get the next $CODX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CODX

    DatePrice TargetRatingAnalyst
    8/12/2022$5.00Buy → Neutral
    Sidoti
    12/29/2021$14.00Buy
    Sidoti
    11/12/2021$16.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CODX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference

      Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital ("DBC") Inaugural Global Conference on May 14, 2025 in New York City. The DBC conference connects emerging growth issuers across multiple sectors with institutional investors. Company representatives will be participating in one-on-one meetings to introduce institutions to the Company's value proposition and to the upcoming Co-Dx PCR* testing platform. More information about the conferen

      5/14/25 9:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results

      SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results:  ●Revenue of $0.1 million, which declined from $0.5 million during the Q1 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the first quarter 2025    ●Operating expenses of $8.6 million decreased by 18.2% from the prior year first quarter    ●Operating loss of $8.6 million compared to operating loss of $10.3 million in Q

      5/8/25 4:01:00 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

      SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The conference call and webcast will be available via: Webcast: ir.codiagn

      4/29/25 7:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Egan Dwight H returned $12,407 worth of shares to the company (51,697 units at $0.24) and was granted 163,334 shares, increasing direct ownership by 21% to 634,494 units (SEC Form 4)

      4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

      5/27/25 4:09:40 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Brown Brian Lee was granted 134,166 shares and returned $11,559 worth of shares to the company (48,161 units at $0.24), increasing direct ownership by 20% to 505,911 units (SEC Form 4)

      4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

      5/27/25 4:09:30 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • President Abbott Richard David was granted 20,000 shares and returned $1,723 worth of shares to the company (7,180 units at $0.24), increasing direct ownership by 92% to 26,735 units (SEC Form 4)

      4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

      5/27/25 4:09:19 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Co-Diagnostics downgraded by Sidoti with a new price target

      Sidoti downgraded Co-Diagnostics from Buy to Neutral and set a new price target of $5.00

      8/12/22 9:07:51 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Sidoti initiated coverage on Co-Diagnostics with a new price target

      Sidoti initiated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $14.00

      12/29/21 8:45:34 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on Co-Diagnostics with a new price target

      HC Wainwright & Co. reiterated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $15.00 from $16.00 previously

      11/12/21 6:13:11 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    Leadership Updates

    Live Leadership Updates

    See more
    • Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

      SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO). Prior to his new role at the Com

      4/4/24 9:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Appoints Chief Regulatory Affairs Officer

      SALT LAKE CITY, Aug. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Ivory Chang as the Company's Chief Regulatory Affairs Officer. Ms. Chang's in-depth regulatory affairs experience has included time spent with several notable names in the diagnostics industry, including Roche, Boston Scientific, BD Biosciences, Cepheid, Thermo Fisher Scientific, and more. Her background has i

      8/29/23 9:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

      SALT LAKE CITY, Nov. 1, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Poritz, PhD as the Company's new Chief Scientific Officer ("CSO"). Dr. Poritz is a Harvard University and UC San Francisco educated molecular biologist with more than 30 years of experience in the application of PCR and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection, who has also served as a reviewer for more than 30 different NIH/NIAID study sections focusing on inf

      11/1/22 9:32:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    SEC Filings

    See more
    • Co-Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Co-Diagnostics, Inc. (0001692415) (Filer)

      5/29/25 4:30:38 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Co-Diagnostics Inc.

      10-Q - Co-Diagnostics, Inc. (0001692415) (Filer)

      5/8/25 4:10:37 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Co-Diagnostics, Inc. (0001692415) (Filer)

      5/8/25 4:05:13 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

      SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

      2/13/24 5:02:32 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

      SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

      2/9/22 3:43:31 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Co-Diagnostics, Inc. (Amendment)

      SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

      7/12/21 8:29:19 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    Financials

    Live finance-specific insights

    See more
    • Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results

      SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results:  ●Revenue of $0.1 million, which declined from $0.5 million during the Q1 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the first quarter 2025    ●Operating expenses of $8.6 million decreased by 18.2% from the prior year first quarter    ●Operating loss of $8.6 million compared to operating loss of $10.3 million in Q

      5/8/25 4:01:00 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

      SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The conference call and webcast will be available via: Webcast: ir.codiagn

      4/29/25 7:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results

      SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Financial Results: Revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023. Grant revenue totaled $3.1 million while product revenue totaled $0.8 millionOperating expenses of $43.0 million decreased by 5

      3/27/25 4:01:00 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care